Detalles de la búsqueda
1.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood
; 137(19): 2646-2656, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512419
2.
"SpezPat"- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians' understanding of non-small cell lung cancer patients' end-of-life decisions.
BMC Palliat Care
; 21(1): 167, 2022 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36167565
3.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868632
4.
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Haematologica
; 108(10): 2844-2849, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36815369
5.
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Br J Haematol
; 179(3): 410-420, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28990173
6.
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Lancet Oncol
; 15(7): 757-66, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24827808
7.
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Br J Haematol
; 161(2): 204-13, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23432194
8.
Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.
Oncology
; 84(6): 362-70, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23689165
9.
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Lancet Oncol
; 13(12): 1250-9, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23168367
10.
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.
Hemasphere
; 7(7): e917, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427145
11.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Hemasphere
; 7(7): e904, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427146
12.
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Leuk Lymphoma
; 63(2): 326-334, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34668817
13.
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Lancet Haematol
; 9(2): e133-e142, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114151
14.
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Br J Haematol
; 152(4): 401-12, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21689083
15.
Using Instagram to Enhance a Hematology and Oncology Teaching Module During the COVID-19 Pandemic: Cross-sectional Study.
JMIR Med Educ
; 7(4): e30607, 2021 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779777
16.
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Lancet Haematol
; 8(4): e267-e277, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667420
17.
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol
; 8(9): e648-e657, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34450102
18.
Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells.
Ann Hematol
; 89(4): 341-8, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19823823
19.
Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status.
Genes Chromosomes Cancer
; 48(1): 39-54, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18828156
20.
Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
EJHaem
; 1(1): 181-187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35847697